- Home
- ALXO
as 04-18-2025 1:30pm EST
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 76.5M | IPO Year: | 2020 |
| Target Price: | $4.14 | AVG Volume (30 days): | 529.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $17.83 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ALX Oncology Holdings Inc. (ALXO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pons Jaume | ALXO | PRESIDENT & CSO | Feb 19 '25 | Sell | $1.15 | 1,326 | $1,525.17 | 579,388 | |
| Lettmann Jason | ALXO | CHIEF EXECUTIVE OFFICER | Feb 19 '25 | Sell | $1.15 | 2,159 | $2,483.28 | 170,270 | |
| Pinto Shelly | ALXO | SVP, FINANCE AND CAO | Feb 19 '25 | Sell | $1.15 | 550 | $632.61 | 87,352 |
Latest ALX Oncology Holdings Inc. News
ALXO Breaking Stock News: Dive into ALXO Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
Zacks
a month ago
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Insider Monkey
a month ago
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday
GlobeNewswire
a month ago
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
MT Newswires
a month ago
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $3 From $2
MT Newswires
a month ago
ALX Oncology to Cut Workforce by 30% to Support New Clinical Initiatives
GlobeNewswire
a month ago
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
GlobeNewswire
2 months ago
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Compare ALXO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALXO ALX Oncology Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.